SARS-CoV-2 vaccination in children with a history of MIS-C: an international survey
The optimal SARS-CoV-2 vaccine strategy for patients with a history of MIS-C is unclear. We performed an international survey (32 countries) and found substantial variations in vaccine policies. Respondents did not report relapses of MIS-C or other severe inflammatory side effects after SARS-CoV-2 vaccination in 273 patients with a history of MIS-C.
source https://www.jpeds.com/article/S0022-3476(22)00438-3/fulltext?rss=yes
source https://www.jpeds.com/article/S0022-3476(22)00438-3/fulltext?rss=yes
Comments
Post a Comment